Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
07:00am, Wednesday, 08'th May 2024
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in t
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
10:11am, Monday, 06'th May 2024
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $1.76 per share a year ago.
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
08:00am, Monday, 06'th May 2024
Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designati
Why Krystal Biotech (KRYS) Might Surprise This Earnings Season
09:41am, Friday, 03'rd May 2024
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
07:00am, Thursday, 02'nd May 2024
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
07:00am, Friday, 26'th Apr 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
10:36am, Tuesday, 23'rd Apr 2024
The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Wednesday, 17'th Apr 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
07:00am, Thursday, 04'th Apr 2024
Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanc
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
09:51am, Monday, 01'st Apr 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
08:00am, Monday, 01'st Apr 2024
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
08:00am, Monday, 01'st Apr 2024
The top five biotech stocks today have several commonalities. Among them are strong ratings.
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
07:44am, Wednesday, 27'th Mar 2024
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as di
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
05:34pm, Thursday, 14'th Mar 2024
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th
